Combined treatment of high and very high risk prostate cancer: results of neoadjuvant treatment
Open Access
- 18 May 2023
- journal article
- research article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (2) , 31-39
Abstract
Purpose of the study. Assessment of safety and short‑term effectiveness of high and very high‑risk prostate cancer neoadjuvant chemo‑ hormonal treatment without distant metastases.Patients and methods. Combined hormone chemo‑ radiation treatment of 33 patients with prostate cancer of high and very high risk of progression without distant metastases was performed. Metastases to regional lymph nodes were found in 9 patients according to the examination data (MRI, MSCT), no metastases were detected in 24 patients. All patients underwent combined chemohormonal therapy in the amount of 4 courses of docetaxel intravenously at a dose of 75 mg/m2 every 3 weeks as the first stage of treatment. in combination with androgen deprivation therapy with agonists or antagonists of GnRH before performing radical radiation therapy (combined or remote). All patients underwent neoadjuvant hormone therapy: 16 patients – with the use of GnRH antagonists (Degarelix), 17 – with the use of GnRH agonists (Gozerelin/Leuprorelin/Triptorelin). The toxicity of the presented treatment regimen and its immediate effectiveness – the effect on the level of prostate‑s pecific antigen (PSA), prostate volume, and the quality of urination – were evaluated.Results. Treatment regimen was highly effective concerning PSA decrease (from initial median level 79,67 ng/ml to 1,45 ng/ml after neoadjuvant treatment), all subjects responded well, no non‑responders observed. Median prostate volume decreased from 44 cm3 to 25 cm3 after treatment, which guaranteed availability and safety of further radical radiation treatment. Urinary function was restored in all subject with initial urinary retention.Conclusion. Neoadjuvant chemo‑h ormonal treatment was highly effective in PSA level, prostate volume decrease and functional results improvement which secured further radical radiation treatment in one of its types. Toxicity was acceptable, adverse events did not exceed grade II in most cases and did not lead to treatment discontinuation in any cases, while quality of life remained high enough.Keywords
This publication has 10 references indexed in Scilit:
- Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 TrialClinical Genitourinary Cancer, 2020
- Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialJournal of Clinical Oncology, 2019
- SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancerScandinavian Journal of Urology, 2018
- Combined chemohormonalradiation treatment of highand very-high-risk non-metastatic prostate cancerCancer Urology, 2017
- Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomyUrologic Oncology: Seminars and Original Investigations, 2015
- Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancerJournal of Hematology & Oncology, 2014
- Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high‐risk, locally advanced prostate cancerCancer, 2009
- Neoadjuvant docetaxel treatment for locally advanced prostate cancerCancer, 2007
- Radical prostatectomy for clinical T4 prostate cancerCancer, 2006
- Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancerUrology, 2004